Latest news

The MS Trust is delighted that ofatumumab (Kesimpta) has been approved by NICE for people with active relapsing remitting multiple sclerosis.

When the neurologist said the words ‘multiple sclerosis’, my immediate three questions were ‘Am I going to die?’, ‘Am I going to be disabled?’, ‘Can I have children?’

Under-the-skin (subcutaneous) injection of Tysabri (natalizumab) has been approved for UK and Ireland.

As we approach another MS awareness week after what has been a very different last 12 months, Martin Baum reflects on the impact the coronavirus lockdown has had on him.

We've had a number of questions regarding possible side effects and also how to prepare for the second dose. To get some answers to these questions, we have once again spoken to neurologist Alasdair Coles from Addenbroke’s hospital in Cambridge.

The MHRA has granted marketing authorisation for ofatumumab (Kesimpta) for active relapsing remitting MS.

We are looking for young people with a connection to MS to join our team of MSTV reporters.

Researchers have investigated how long it takes for disease modifying drugs to be fully effective at reducing relapses and slowing progression.

Anthony Chapman is a musician who was diagnosed with MS a few years ago. In this article we find out how he started streaming his beat making on Twitch and why he is helping the MS Trust make a theme tune for our new podcast series.

Siblings Al and Bee (9 and 8 years old) have been inspired to help those affected by multiple sclerosis by taking part in Mission:100 this year.

"To forget the life where I once chose exclusion instead of inclusion would mean that I had learned nothing from a time when I chose to live MS and not life."  Martin Baum looks at how MS prepared him for lockdown.

This study compared the effectiveness of amantadine, modafinil and methylphenidate with placebo in people with MS-related fatigue.